GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » FibroGen Inc (NAS:FGEN) » Definitions » ROE %
中文

FibroGen (FibroGen) ROE % : 0.00% (As of Dec. 2023)


View and export this data going back to 2014. Start your Free Trial

What is FibroGen ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. FibroGen's annualized net income for the quarter that ended in Dec. 2023 was $-224.9 Mil. FibroGen's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $-180.7 Mil. Therefore, FibroGen's annualized ROE % for the quarter that ended in Dec. 2023 was N/A%.

The historical rank and industry rank for FibroGen's ROE % or its related term are showing as below:

FGEN's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -44.08
* Ranked among companies with meaningful ROE % only.

FibroGen ROE % Historical Data

The historical data trend for FibroGen's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FibroGen ROE % Chart

FibroGen Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -15.01 -40.35 -91.88 -312.90 -

FibroGen Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -10,895.25 - - - -

Competitive Comparison of FibroGen's ROE %

For the Biotechnology subindustry, FibroGen's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


FibroGen's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, FibroGen's ROE % distribution charts can be found below:

* The bar in red indicates where FibroGen's ROE % falls into.



FibroGen ROE % Calculation

FibroGen's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-284.232/( (-21.447+-204.166)/ 2 )
=-284.232/-112.8065
=N/A %

FibroGen's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-224.928/( (-157.169+-204.166)/ 2 )
=-224.928/-180.6675
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.


FibroGen  (NAS:FGEN) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-224.928/-180.6675
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-224.928 / 108.552)*(108.552 / 441.9775)*(441.9775 / -180.6675)
=Net Margin %*Asset Turnover*Equity Multiplier
=-207.21 %*0.2456*N/A
=ROA %*Equity Multiplier
=-50.89 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-224.928/-180.6675
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-224.928 / -227.068) * (-227.068 / -216.78) * (-216.78 / 108.552) * (108.552 / 441.9775) * (441.9775 / -180.6675)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.9906 * 1.0475 * -199.7 % * 0.2456 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


FibroGen ROE % Related Terms

Thank you for viewing the detailed overview of FibroGen's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


FibroGen (FibroGen) Business Description

Traded in Other Exchanges
Address
409 Illinois Street, San Francisco, CA, USA, 94158
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates.
Executives
Jeffrey William Henderson director 7000 CARDINAL PLACE, DUBLIN OH 43017
Enrique A Conterno director, officer: Chief Executive Officer LILLY CORPORATE CENTER, INDIANAPOLIS IN 46285
Thane Wettig officer: Chief Commercial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Christine Chung officer: SVP, China Operations C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Jeffrey L Edwards director 2525 DUPONT DR, IRVINE CA 92612
Aoife Brennan director 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139
Benjamin Cravatt director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Suzanne Blaug director C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Maykin Ho director C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE MA 02139
James A Schoeneck director C/O DEPOMED, INC., 1360 O'BRIEN DRIVE, MENLO PARK CA 94025
Mark Eisner officer: Incoming Chief Medical Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Juan Graham officer: Chief Financial Officer C/O FIBROGEN, INC., 409 ILLINOIS STREET, SAN FRANCISCO CA 94158
Kearns Thomas F Jr director P O BOX 587, WARSAW IN 46581-0587
Pat Controneo officer: VP, Finance and CFO C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158
Kalevi Kurkijarvi director C/O FIBROGEN, INC., 409 ILLINOIS ST.,, SAN FRANCISCO CA 94158